CDNA
CareDx, Inc.
Diagnostics & Research · Healthcare · United States
71.52
close · 2026-10-29
value
9
cheaper than peers9
quality
97
stronger fundamentals97
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| price to book | 8.65× | 33 |
| price to sales | 8.08× | 31 |
| forward P/E | 55.44× | 13 |
| EV to EBITDA | 271.63× | 3 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 52.2% | 95 |
| debt to equity | 4.5% | 91 |
| return on equity | 29.5% | 88 |
| operating margin | 0.2% | 52 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | $112.2M |
| employees | 761 |
| first trade | 2014-07-17 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.40 | 0.93 | -3.54 | -1.44 |
| free cash flow | $35.4M | $31.6M | -$27.6M | -$49.6M |
| net income | -$21.4M | $52.5M | -$190.3M | -$76.6M |
| revenue | $379.8M | $333.8M | $280.3M | $321.8M |
| unusual items | -$5.7M | $96.3M | -$96.3M | $107,000 |